ALK-Abello A/S Series B | Mutual Funds
Mutual Funds that own ALK-Abello A/S Series B
ATP Group Portfolio
791,631
7.82%
197,165
0.1%
12/31/2017
Jupiter European Fund
369,238
3.65%
0
0.86%
02/28/2018
Government Pension Fund - Global (The)
198,755
1.96%
7,808
0%
12/31/2017
Wellington Mgmt. Port (Dublin) Plc - Strategic European Equity
113,000
1.12%
85,000
0.81%
12/31/2017
BankInvest Danmark
99,334
0.98%
0
2.69%
01/31/2018
Vanguard Total International Stock Index Fund
92,812
0.92%
3,976
0.01%
07/31/2018
Jupiter Global Fund - European Growth Fund
90,193
0.89%
0
0.51%
02/28/2018
Nordea Nordic Small Cap
67,881
0.67%
45,801
0.61%
04/30/2018
Brown Advisory WMC Strategic European Equity Fund
40,842
0.4%
0
0.83%
08/31/2018
DFA Continental Small Company Series
36,938
0.37%
498
0.11%
01/31/2018
| Address |
Bøge Allé 6-8
Hørsholm CR 2970
Denmark
|
|
Employees
|
- |
| Website |
http://www.alk.net |
| Updated |
07/08/2019 |
| ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. |
